Mexican S.E.
18:00:00 2024-07-16 EDT
5-day change
1st Jan Change
17.83
MXN
-1.82%
-5.41%
+25.92%
An undisclosed buyer agreed to acquire Casa Marzam, S.A. de C.V. from Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B).
An undisclosed buyer agreed to acquire Casa Marzam, S.A. de C.V. from Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B) on June 12, 2024.
An undisclosed buyer agreed to acquire Casa Marzam, S.A. de C.V. from Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B).
07-11
CI
Mexican Stocks Reverse Two-Session Losing Streak
07-08
DJ
Tranche Update on Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B)'s Equity Buyback Plan announced on March 20, 2013.
06-26
CI
Mexican Stocks Flat As IPC Index Holds Steady
06-20
DJ
Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend
06-13
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 25, 2024
04-25
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
04-24
CI
Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend
03-13
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2023 Earnings Call, Feb 22, 2024
02-22
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-21
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Full Year Ended December 31, 2023
02-21
CI
Tranche Update on Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B)'s Equity Buyback Plan announced on March 20, 2013.
02-20
CI
Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend Payment
12-13
CI
Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America
11-29
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q3 2023 Earnings Call, Oct 26, 2023
23-10-26
Tranche Update on Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B)'s Equity Buyback Plan announced on March 20, 2013.
23-10-24
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-24
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q2 2023 Earnings Call, Jul 27, 2023
23-07-27
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-07-26
CI
Tranche Update on Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B)'s Equity Buyback Plan announced on March 20, 2013.
23-07-25
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2023 Earnings Call, Apr 27, 2023
23-04-27
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-27
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V. - Analyst/Investor Day
23-03-08
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2022 Earnings Call, Feb 23, 2023
23-02-23
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
23-02-22
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
More about the company
Last Close Price
17.83
MXN
Average target price
20
MXN
Spread / Average Target
+12.17%
Consensus
1st Jan change
Capi.
+25.92% 971M +55.35% 848B +31.64% 627B -0.10% 363B +15.47% 318B +13.10% 299B +15.51% 243B +16.72% 225B +16.54% 179B +4.31% 167B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
